Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial
Chadi G. Abdallah, John D. Roache, Ralitza Gueorguieva, Lynnette A. Averill, Stacey Young‐McCaughan, Paulo Shiroma, Prerana Purohit, Antoinette Brundige, William Murff, Kyung-Heup Ahn, Mohamed Sherif, Eric J. Baltutis, Mohini Ranganathan, Deepak Cyril D’Souza, Brenda Martini, Steven M. Southwick, Ismene L. Petrakis, Rebecca R. Burson, Kevin B. Guthmiller, Argelio L. López-Roca, Karl A. Lautenschlager, John P. McCallin, Matthew B. Hoch, Alexandar Timchenko, Sergio E. Souza, Charles E. Bryant, Jim Mintz, Brett T. Litz, Douglas E. Williamson, Terence M. Keane, Alan L. Peterson, John H. Krystal
Topics & Concepts
KetaminePlaceboRandomized controlled trialTolerabilityMedicineDissociativeDiscontinuationAnesthesiaAntidepressantHamilton Rating Scale for DepressionClinical trialMajor depressive disorderPsychiatryPsychologyAdverse effectInternal medicineAnxietyCognitionAlternative medicinePathologyTreatment of Major DepressionAnesthesia and Neurotoxicity ResearchTryptophan and brain disorders